IQM Quantum Computers Appoints Jan Goetz as Sole CEO to Lead Next Phase of Global Growth
Jan Goetz becomes sole CEO, while Søren Hein is appointed Chief Operating Officer and Deputy CEO. Former Co-CEO Mikko Välimäki transitions out of his commercial role and remains as an advisor until 31 March 2026. This new leadership structure is designed to strengthen IQM's global strategic direction, planning and execution.
IQM Quantum Computers, a global leader in full-stack superconducting quantum computers, today announced a transition from its Co-CEO structure to a single Chief Executive Officer model.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260126737805/en/
From left to right: Jan Goetz (Co-founder & CEO) and Søren Hein (Chief Operating Officer and Deputy CEO)
Co-founder and current Co-CEO Dr Jan Goetz becomes sole CEO effective since January 1st, following a resolution passed by the IQM board. In addition, Dr Søren Hein has been appointed Chief Operating Officer and Deputy CEO.
As part of the transition, Mikko Välimäki steps down from his commercial role following a successful tenure as Co-CEO. He will continue to support the company as an advisor until 31 March 2026 to ensure continuity and a smooth transition.
“Our dual CEO approach has served IQM well over the past two years, and I want to thank Mikko Välimäki for his significant contributions,” said Dr. Sierk Poetting, Chairman of IQM’s Board of Directors. “Moving to a single-CEO structure reflects the maturity of the organisation and positions IQM to deliver the next phase of sustainable global expansion and long-term growth.”
Since its founding in 2018, IQM has grown into a major global quantum computing brand. Over the past year, IQM sold and shipped more on-premises quantum computers than any of its competitors and completed the largest Series B funding round in quantum outside the US.
The new leadership structure supports IQM’s continued focus on scaling quantum computers for industrial and commercial use. “I am delighted to welcome Søren to his new role. We will continue to expand and strengthen our leadership team to prepare for the next phase of strong growth, in line with our technology roadmap and long-term vision,” said Goetz.
He added: “IQM is well positioned to meet the evolving needs of AI-driven organisations and high-performance computing centres. This new structure will help us accelerate progress towards fault-tolerant quantum computing and deliver greater value to our customers and partners.”
Commenting on his appointment, Søren Hein said: “IQM has built an incredible team and culture of innovation. As we scale globally, I look forward to strengthening our operations, accelerating quantum adoption, and supporting long-term commercial success.”
Editor’s note:
About Jan Goetz:
In 2018, Goetz spun out IQM from Aalto University and VTT Technical Research Center of Finland together with his co-Founders and raised over $600M of capital for the company since then.
He was on the Board of the European Innovation Council EIC where he now serves as an EIC ambassador, and he holds a Board seat in the European Quantum Industry Consortium QuIC. He is also and member of the German Federal Economic Senate, an EIC Scaling Club Council member, member of the Hall of Future, as well as a Digital Leader and Global Innovator at the World Economic Forum (WEF).
In 2024, WirtschaftsWoche Magazin selected him as one of 30 executives to shape Germany, in 2023, he was selected as Founder of the Year by Handelsblatt. In 2020, Capital magazine selected him as one of 40 under 40 in Germany and he received an entrepreneurship award from the KAUTE Foundation.
Goetz did his doctorate on superconducting quantum circuits at TU Munich and worked as a Marie-Curie Fellow in Helsinki at Aalto University, where he holds the title of docent.
About Søren Hein:
Søren brings over 30 years of experience as a technology executive and investor across Europe and North America. He previously led Deeptech investments at MIG Capital, which also led IQM’s seed round in 2019. In addition, Hein has co-founded and run a startup in electric motors and served as Chief Technology Officer of the Wireless Systems business unit at Infineon. He holds a Ph.D. in Electrical Engineering and Computer Science from UC Berkeley and an MBA from INSEAD.
About IQM Quantum Computers:
IQM is a global leader in superconducting quantum computers. IQM provides both on-premises full-stack quantum computers and a cloud platform to access its computers. IQM customers include the leading high-performance computing centers, research labs, universities, and enterprises that have full access to IQM's software and hardware. IQM has over 300 employees with headquarters in Finland and a global presence in France, Germany, Italy, Japan, Poland, Spain, Singapore, South Korea, and the United States.
View source version on businesswire.com: https://www.businesswire.com/news/home/20260126737805/en/
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Aesyra Demonstrates Significant Sleep Bruxism Reduction in Clinical Study26.1.2026 09:00:00 CET | Press release
Aesyra SA, a Swiss medtech company developing innovative digital therapeutics for dental and sleep-related disorders, today announced the successful completion of its clinical investigation evaluating the efficacy and safety of AesyBite™ Active, an intelligent oral appliance designed to treat and prevent sleep bruxism through biofeedback. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260126533019/en/ AesyBite Custom smart nightguard by Aesyra SA. The clinical investigation demonstrated that AesyBite™ Active achieved a statistically significant and clinically meaningful reduction in sleep bruxism activity, exceeding the predefined performance target. Strong and robust clinical outcomes In the study (Identifier: NCT06153810), involving 26 adult patients with confirmed sleep bruxism, activation of the AesyBite Active biofeedback system resulted in a 60.6% reduction in total sleep bruxism duration per hour compared to baseline
Franklin Templeton Aligns Alternative Credit Firms Under BSP Brand26.1.2026 08:58:00 CET | Press release
Benefit Street Partners and Alcentra align under a single, refreshed BSP brand.Move reflects client demand for a specialist, integrated and global credit platform.Franklin Templeton’s alternative credit platform on track to exceed $100bn in 2026.BSP outlines further growth plans including expansion in the Middle East and Asia.New research says 51% of institutional investors will increase credit allocation in 2026.81% of institutions say a specialist focus on credit is the top attribute for performance. Franklin Templeton’s US and European alternative credit businesses, Benefit Street Partners and Alcentra, have now aligned under an updated Benefit Street Partners (BSP) brand. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260123270080/en/ David Manlowe, CEO of Benefit Street Partners The move is the final step in BSP and Alcentra’s integration – two pioneering alternative credit firms that Franklin Templeton acquired in 2019
Samsung Epis Holdings Reports Fourth Quarter and Fiscal Year 2025 Financial Results26.1.2026 08:00:00 CET | Press release
In its first financial results announcement after the spin-off, Samsung Bioepis recorded FY2025 revenue of KRW 1.672 trillion, highest annual revenue in its 14-year historyExcluding milestone revenue, annual sales revenue grew 28% year-over-year (YoY), recording KRW 1.626 trillion, with 101% YoY growth in operating profit to KRW 330.8 billion Samsung Epis Holdings (KRX: 0126Z0), an investment company dedicated to innovations in biopharmaceuticals and biotechnology, today announced financial results for the fourth quarter and fiscal year 2025. “We are very pleased to report strong year-to-date sales growth in our first financial results following the spin-off. Our organic growth has been driven by solid performance across our biosimilars portfolio," said Kyung-Ah Kim, President and Chief Executive Officer (CEO) of Samsung Epis Holdings. “We are continuing to make meaningful progress in our regulatory and commercial milestones with our existing biosimilars portfolio, while strategically
Syngenta and Statkraft Sign Five-Year Virtual Power Purchase Agreement26.1.2026 08:00:00 CET | Press release
Virtual wind PPA with guarantees of origin to decarbonize Syngenta's plants in Europe Important element in carbon reduction journey for Syngenta AG Syngenta, one of the world’s biggest agricultural innovation companies, and Statkraft, a leading provider of innovative green energy solutions in Europe, have signed a virtual power purchase agreement (vPPA) covering Syngenta’s CP & Seeds operations for a period of five years. The volume amounts to 125 GWh per year and a total of 625 GWh of green electricity by the end of the contract in 2030. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260125701845/en/ Syngenta and Statkraft sign five-year virtual power purchase agreement With the vPPA, Statkraft is supporting Syngenta in advancing its sustainability strategy through the purchase of renewable energy. "This is Syngenta's first vPPA, marking a pivotal step in our decarbonization strategy," said Rachel Stenson Bugnon, Global Hea
Merz Therapeutics Submits Application to the European Medicines Agency for New Indication of XEOMIN® in Pediatric Spasticity26.1.2026 08:00:00 CET | Press release
Merz Therapeutics, a leading player in neurology-focused specialty pharma, today announced that it has completed the regulatory submission for XEOMIN® (incobotulinumtoxinA) for the treatment of spasticity of the lower and upper limb in children and adolescents aged 2–17 years in the European Union (EU) and European Economic Area (EEA). If approved, the indication would expand access to an established botulinum neurotoxin therapy for some of the youngest and most vulnerable patients across Europe. Spasticity is a common and often debilitating condition in children and adolescents with certain neurological conditions, leading to increased muscle tone that can significantly limit movement, function and independence. One of the most common underlying causes of spasticity in children is cerebral palsy (CP), the most frequent motor disability in childhood, with spastic forms accounting for approximately 80% of all cases. In more severe cases, spasticity associated with CP can also affect spe
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom